Mainz Biomed is a diagnostics & research business based in the US. Mainz Biomed shares (MYNZ) are listed on the NASDAQ and all prices are listed in US Dollars. Mainz Biomed employs 65 staff and has a trailing 12-month revenue of around $895,479.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.33 |
|---|---|
| 52-week range | $0.31 - $4.38 |
| 50-day moving average | $0.38 |
| 200-day moving average | $0.82 |
| Wall St. target price | $2.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.62 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.3265 from 2024-09-06
| 1 week (2024-08-30) | -7.69% |
|---|---|
| 1 month (2024-08-08) | -0.76% |
| 3 months (2024-06-07) | -59.09% |
| 6 months (2024-03-08) | -66.47% |
| 1 year (2023-09-08) | -89.92% |
|---|---|
| 2 years (2022-09-08) | -96.47% |
| 3 years (2021-09-04) | N/A |
| 5 years (2019-09-04) | N/A |
| Revenue TTM | $895,479 |
|---|---|
| Gross profit TTM | $177,622 |
| Return on assets TTM | -93.42% |
| Return on equity TTM | -303.2% |
| Profit margin | 0% |
| Book value | $0.15 |
| Market Capitalization | $7.7 million |
TTM: trailing 12 months
We're not expecting Mainz Biomed to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Mainz Biomed's shares have ranged in value from as little as $0.306 up to $4.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mainz Biomed's is 0.152. This would suggest that Mainz Biomed's shares are less volatile than average (for this exchange).
To put Mainz Biomed's beta into context you can compare it against those of similar companies.
Mainz Biomed N. V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. .
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.